Remebot bags $66m Series D

Neurosurgery medical robots developer Beijing Baihui Weikang Technology Co., Ltd (Remebot) said that it has raised as much as 430 million yuan ($66 million) in a Series D round of financing led by Beijing Zhongguancun Longmen Investment, a tech-driven venture capital firm.

The round was joined by MatrixPartners China, China Securities, Xin Ding Capital, Heyin Capital, and Chord Capital, a 1 billion yuan ($153 million) fund that focuses on culture, media, and internet, Remebot posted on WeChat.

Remebot will invest about 300 million yuan ($46 million) for its flagship neurosurgical robot Remebot, and it will aim to pour the rest of the proceeds for the market expansion of its dental implant robot, the company said.

Set up in 2010 in Beijing, Remebot is dedicated to designing and distributing surgical robots that primarily cater to neurosurgery. Besides, it has taken efforts to foray into the dental implant segment.

Before the current round, Remebot had closed seven other rounds of funding from a slew of prominent investors like ZhenFund, PE firm Puhua Capital, new industry city investment focused China Fortune Land Development, and Zhencheng Capital, among others.

The company’s founder, chairman and CEO Liu Da said that high-quality investors and sufficient capital injection will further consolidate the company’s leading position in the field of medical surgical robots. In the future, the company will insist on independent innovation, continue to develop new products, and build complete products. Matrix provides minimally invasive, precise and efficient medical surgical robot products and services.

Matrix Partners Chin said that new medical devices driven by software algorithms are an important layout direction of Jingwei in the digital medical field. Surgical robots that combine multiple technologies such as image fusion and navigation and positioning have a clear and strong industry driving force in achieving minimally invasive surgery, improving surgical accuracy, shortening surgical duration, and inclusive of grassroots. Bohui Weikang has a top-notch team in the field of domestic surgical robotics, has deep technology and R&D accumulation in neurosurgery, dental implantation and other fields, and is in a leading position in the clinical and commercialization of the industry. We look forward to the company's continuous innovation and rapid development to create greater value for patients and doctors.